In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.

Bayer HealthCare's Eylea (aflibercept solution for injection into the eye) has been approved by the European Commission for the treatment of visual impairment due to diabetic macular oedema (DMO).

Here's what macular degeneration is, what causes it and how you can expect it to be treated if it affects you or a loved one. Macular degeneration, also known as age-related macular degeneration ...

This swelling can lead to serious vision problems ... following its 2021 approval for wet (neovascular) age-related macular degeneration. The ranibizumab injection (Lucentis) was first approved ...

and diabetic macular oedema (DMO - and will be sold in the EU by Biogen. Like Lucentis, the biosimilar can also be used to treat proliferative diabetic retinopathy (PDR), macular oedema caused by ...

The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with diabetic macular edema (DME) who have previously responded to at least 2 ...

(RTTNews) - EyePoint Pharmaceuticals, Inc. (EYPT), Wednesday announced positive six-month results from the ongoing Phase 2 VERONA clinical trial, evaluating Duravyu for the treatment of diabetic ...

Regeneron Pharmaceuticals has reported positive outcomes from the Phase III QUASAR trial of Eylea HD (aflibercept) 8mg injection in treating individuals with macular oedema following retinal vein ...